Evidence map›Paper›PMID 30065051›Full record

ArticleBMJ case reports2018

Asmita Gupte, Anupama Matcha, Michael Lauzardo

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Asmita GupteDivision of Infectious Diseases and Global Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Anupama MatchaDivision of Hospitalist Medicine, University of North Carolina Regional Physicians, High Point, North Carolina, USA.
Michael LauzardoDivision of Infectious Diseases and Global Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID http://orcid.org/0000-0002-7096-4185
University of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BCG has been used as intravesical immunotherapy for the treatment of bladder carcinoma. However, this treatment is not harmless and may lead to complications, with a reported incidence of systemic BCG infection ranging from 3% to 7%. We report a case of culture-proven

Indexed as

Adjuvants, ImmunologicAdministration, IntravesicalAgedAntitubercular AgentsBCG VaccineEquipment ContaminationHumansMaleMitomycinMycobacterium bovisOsteomyelitisTreatment OutcomeTuberculosis, SpinalUrinary Bladder NeoplasmsAdjuvants, ImmunologicAntitubercular AgentsBCG VaccineMitomycinbone and joint infectionsnosocomial infectionstuberculosis

Identifiers

PMID30065051
PMCPMC6069907
OpenAlexW2886234224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.